In short there is no one cure or cure for all schizophrenics, however we can make a lot of improvements in what we now do to patients and make an improvement in their lives.
There are many different risk factors that explain the link between schizophrenia and bipolar disorder, and it can also be found linked to a family history. A possible contributing factor to schizophrenia is malnutrition, which is related to malnutrition as a risk factor. However, it can also be linked to certain parasites and viruses, as well. In the US, the risk of an individual diagnosed with schizophrenia is approximately 1.42 times higher than it is in the general population.
The incidence and prevalence rates of schizophrenia in the United States differ in different regions of the country. While the rate of incidence remains relatively stable, the prevalence of schizophrenia in the United States has increased steadily, particularly between 1991 and 2006. There appears to be a difference in the incidence and prevalence of schizophrenia across Hispanic and non-Hispanic racial/ethnic groups, and a greater prevalence of milder disease in the United States, especially among African American men.
A variety of signs and symptoms are encountered from the presentation of schizophrenia. Although the signs vary from one individual to another, some of these signs may be useful in facilitating clinical diagnosis.
There is little evidence that one type of treatment has an advantage over another. One option for managing chronic schizophrenia is an antipsychotic drug which is often effective and relatively tolerated. A range of additional options and approaches are available.
Data from a recent study of this study suggest that schizophrenia is a spectrum of psychotic disorders that manifest through the occurrence of symptoms in the form of hallucinations, delusions, disorganized or catatonic symptoms. In addition, these symptoms cause distress for other close relatives. The burden of the disease, or the cost to the individual, to society, and to the individual is extremely high. It may therefore be difficult to detect the disease early.
Clozapine is a very potent inhibitor of CYP2D6 activity and this explains its high rate of side-effects following acute dosing. There appears to be no evidence to suggest CYP2D6 plays a significant role in the metabolism of clozapine in subjects who may be co-medicated with a CYP2D6 inhibitor such as fluoxetine.
CLZ appears to be well tolerated for people with ICD. In general, patients treated with CLZ are less likely to experience side effects compared to those who are not receiving CLZ. This contrasts with preapproval studies where there was little difference between the tolerability of those being treated with CLZ, and those being treated with other antipsychotics.
The FDA’s approval of the generic version of divalproex sodium, marketed as the generic name Clozaril, signifies that divalproex now is available as a generic and is available to the general public and not only to those in the medical community who are willing to pay for the drug. The development of the generic divalproex sulfate is less new than the new development of clozapine itself, which has been approved by the FDA and is available for the treatment of schizophrenia by prescription in combination with a low dose of an antipsychotic agent.
Patients taking clozapine will experience common side effects. However, these are not necessarily dangerous. In fact, if clozapine is used for a long period of time, the most prevalent side effects are less common and do not require urgent attention.
The severity of the course of psychotic disorders can be rated. We developed criteria based on previous research and validated them in a large sample of patients. Although they were defined for clinical assessment in the outpatient setting, there is a high agreement between their ratings by the patients and by independent observers. Thus, we believe our criteria will allow assessment of the severity of schizophrenic disorders both in the outpatient and inpatient settings.
The use of randomised placebo control trials to test a potential disease-modifying treatment is now accepted in medicine as the standard for assessing the efficacy of drugs for use in clinical practice. Randomised, placebo-controlled, double-blind trials are now required prior to any drugs being approved for use, even if there is some suggestion of benefit from other types of study. Given recent developments, this recommendation may come to be seen as an unjustified delay in the approval of an important treatment for patients with schizophrenia.